WANG, Shaoke,TSE, Theresa Y Y,ZHANG, Zhao,DOU, Ping,XU, Jingrui,TIAN, Hongwei,ZHANG, Wanyu
申请号：
AU2017101878
公开号：
AU2017101878A4
申请日:
2017.04.27
申请国别(地区):
AU
年份:
2020
代理人:
摘要：
#$%^&*AU2017101878A420200618.pdf#####ABSTRACT Disclosed is a gynostemma pentaphyllum-containing health care pharmaceutical composition for preventing hyperlipidemia, hypertension, hyperglycemia and gout. The pharmaceutical composition is prepared by mixing raw materials of gynostemma pentaphyllum, folium eucommiae, folium mori, semen plantaginis, herba lophatheri, pueraria mirifica powder, pelargonium graveolens and sanguisorba minor, and the raw materials are in percentage by mass: 40-70% of gynostemma pentaphyllum, 5-20% of folium eucommiae, 5-20% of folium mori, 5-10% of semen plantaginis, 2-10% of herba lophatheri, 2-10% of pueraria mirifica powder, 2-8% of pelargonium graveolens and 2-8% of sanguisorba minor. The gynostemma pentaphyllum is prepared by mixing diploid gynostemma pentaphyllum leaves and tetraploid gynostemma pentaphyllum leaves according to a ratio. The pharmaceutical composition is mainly aimed at people who suffer from hyperlipidemia, hypertension, hyperglycemia and hyperuricemia, and used for preventing and treating the "four hypers".
